|
Solagran Limited is an Australian pharmaceutical company which has developed a range of biologically-active multifaceted therapeutic substances derived from the live elements of the green needles of certain species of conifer tree known as ''Bioeffectives''. ==History== Solagran brings together a significant history (). Research into ''Bioeffectives'' has been undertaken for a period of approximately 80 years involving more than 3.5 million PhD. and DSc. research hours (encompassing 74 PhD.s and 80 DSc.s), making it arguably the most substantial botanicals research program ever undertaken. The extent of the effort is evidenced by the fact that the company's intellectual property encompasses 22 patents (). The ''Bioeffectives'' story began in Russia in the early 1930s. Intrigued by the vitality of conifer trees that remain disease free in temperature extremes ranging from ± 40 degrees Celsius, and in daylight of between 2 and 22 hours per day, a scientific team at the St Petersburg Forest Technical Academy began its investigation into the composition of the conifer tree needles. They discovered that, in conifer trees just as in our own bodies, specific combinations of compounds are responsible for health and vital functions. During World War II, a precursor to ''Bioeffective A'', one of the company's ''Bioeffectives'', was approved by the Russian Surgeon General for use by the military and civilian population as a multivitamin, anti-bacterial wound-healing substance. According to Solagran, it also helped save many lives during the 900-day siege of Leningrad (now St Petersburg). Over the following decades, new products were developed and trialled in leading Russian and European institutions for medical, cosmetic, agricultural and veterinary applications. Between 1950 and 1975, several ''Bioeffectives'' were entered into the Russian Pharmacopoeia and used on a national scale. ''Bioeffectives'' were also used with great success to treat people exposed to radiation as a result of the Chernobyl disaster. In 1990, one of the leaders of the research effort in the Soviet Union, Dr Vagif Soultanov, now Executive Chairman of Solagran, went to Australia to work at their Government's peak scientific body, Commonwealth Scientific and Industrial Research Organisation, as part of an inter-government scientific exchange programme. In 1995, the Australian company Solagran was formed to fund the ongoing R&D effort. In 1998, ownership of all intellectual property associated with ''Bioeffectives'' was transferred to Solagran. After over three decades of working in the pharmaceutical industry Solagrans managing director gave his position to his brother in-law after the passing of his wife. The company listed on the Australian Securities Exchange in 2003. Since then, in conjunction with the St Petersburg Forest Technical Academy, Solagran has completed a large number of pre-clinical and clinical trials. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Solagran」の詳細全文を読む スポンサード リンク
|